Data Uncovers New Gene Signature to Help
Understand Persistence in CAR T-cells
PLEASANTON, Calif., July 5, 2023
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a
leader in single cell and spatial biology, announced today that its
single-cell genomic technologies were used in a study published in
the journal Nature Medicine about new gene signatures that
explain why some children with leukemia have longer remission after
CAR T-cell therapy. The collaborative research project was
conducted by researchers from Great Ormond Street Hospital (GOSH),
the Wellcome Sanger Institute and the UCL Great Ormond Street
Institute of Child Health (UCL GOS ICH).
Researchers conducting the study, "Transcriptional signatures
associated with persisting CD19 CAR-T cells in children with
leukemia," used Chromium Single Cell Gene Expression
technologies and T-cell receptor sequencing of samples to look at
what makes the long-lasting CAR T-cells unique. These helped
identify a genetic signature of the CAR T-cells that persisted in
the body long-term – an important predictor of durable remission.
The data was from the CARPALL trial, which used molecular
features and clonal dynamics of CD19 CAR T-cells of 10 children
with relapsed or refractory B-cell acute lymphoblastic.
Ben Hindson, Co-founder and Chief
Scientific Officer at 10x Genomics, said, "Single cell genomics is
a powerful tool that is transforming cancer research and our
understanding of health and disease. We are so proud to have 10x
technologies behind this incredible breakthrough. We celebrate the
achievements of the research team and the selfless dedication of
the families who made this study possible. We look forward to
continuing to give researchers the technologies needed to fuel new
biological discoveries and ultimately help improve patient
care."
Using Chromium Single Cell Gene Expression products, researchers
identified a unique double negative phenotype of long-lasting CAR
T-cells, which provides insights into how these cells survive and
remain active in the body. These key genes appeared to enable the
CAR T-cells to persist and therefore allow the children to live
cancer free long-term. The findings may lead to discovering new
biomarkers that could predict the long-term durability of CAR
T-cell therapies and provide better treatment options for
patients.
Dr. Sam Behjati, co-senior author, Group Lead and Wellcome
Senior Research Fellow at the Wellcome Sanger Institute and
Honorary Consultant Paediatric Oncologist at Addenbrooke's
Hospital, Cambridge, said, "This study is a fantastic step forward
in our understanding of CAR T-cell persistence and illustrates the
power of collaborative science and combining pioneering clinical
research with cutting-edge genomic science. It is crucial that we
continue to develop and build on these new treatments to help more
children with leukaemia across the world."
About 10x Genomics
10x Genomics is a life science
technology company building products to interrogate, understand and
master biology to advance human health. Our integrated solutions
include instruments, consumables and software for analyzing
biological systems at a resolution and scale that matches the
complexity of biology. 10x Genomics products have been adopted by
researchers around the world including in all of the top 100 global
research institutions as ranked by Nature in 2021 based on
publications and all of the top 20 global pharmaceutical companies
by 2021 research and development spend and have been cited in over
5,000 research papers on discoveries ranging from oncology to
immunology and neuroscience. Our patent portfolio comprises more
than 1,750 issued patents and patent applications.
About the Wellcome Sanger Institute
The Wellcome
Sanger Institute is a world leading genomics research centre. We
undertake large-scale research that forms the foundations of
knowledge in biology and medicine. We are open and collaborative;
our data, results, tools and technologies are shared across the
globe to advance science. Our ambition is vast – we take on
projects that are not possible anywhere else. We use the power of
genome sequencing to understand and harness the information in DNA.
Funded by Wellcome, we have the freedom and support to push the
boundaries of genomics. Our findings are used to improve health and
to understand life on Earth. Find out more at www.sanger.ac.uk or
follow us on Twitter, Facebook, LinkedIn and on our Blog.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are subject
to the "safe harbor" created by those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "enable," "should," "expect," "plan," "anticipate,"
"could," "intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential," "would," "likely," "seek" or
"continue" or the negatives of these terms or variations of them or
similar terminology, but the absence of these words does not mean
that a statement is not forward-looking. These forward-looking
statements include statements regarding 10x Genomics, Inc.'s
expectations regarding the ability of our single cell products to
transform our understanding of health and disease and improve
patient care. These statements are based on management's current
expectations, forecasts, beliefs, assumptions and information
currently available to management, and actual outcomes and results
could differ materially from these statements due to a number of
factors. The material risks and uncertainties that could affect 10x
Genomics, Inc.'s financial and operating results and cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release include those
discussed under the captions "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" in the company's most recently-filed 10-K and elsewhere
in the documents 10x Genomics, Inc. files with the Securities and
Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. These
forward-looking statements do not reflect the potential impact of
any future acquisitions, mergers, dispositions, joint ventures or
investments 10x Genomics, Inc. may make. Further, such
forward-looking statements may not accurately or fully reflect that
our products could be subject to regulation by the FDA or other
regulatory agencies, and are available as research-use-only and are
not intended for clinical or diagnostic uses, and that our business
depends significantly on research and development spending by
research institutions. The forward-looking statements in this press
release are based on information available to 10x Genomics, Inc. as
of the date hereof, and 10x Genomics, Inc. disclaims any obligation
to update any forward-looking statements provided to reflect any
change in our expectations or any change in events, conditions, or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics, Inc.'s views as of any
date subsequent to the date of this press release.
Disclosure Information
10x Genomics, Inc. uses filings
with the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/car-t-cell-study-enabled-by-10x-genomics-single-cell-technology-published-in-nature-medicine-301870534.html
SOURCE 10x Genomics, Inc.